Pipeline
Our programs are built on a first-in-class DES1 inhibition platform with broad applicability across CKM diseases. By targeting ceramide overproduction upstream, we aim to impact multiple renal, cardiac, and metabolic indications.
Lead asset: CNT2130 currently in clinical trials
A once-daily, oral DES1 inhibitor with demonstrated therapeutic activity across kidney, cardiac, hepatic, and metabolic endpoints. Supported by extensive human lipidomic, genetic, and pharmacological validation and IND-enabling safety data, CNT2130 has a clear path to clinical proof-of-concept in DKD and beyond.
Program
Phase
CNT2130
Phase 1
CNT2198
Preclinical
2nd-Gen DES1
Inhibitors
Discovery